Drug intelligence / Profile preview

ampicillin + clindamycin + metronidazole

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination antibiotic therapy consisting of ampicillin (a penicillin-class antibiotic), clindamycin (a lincosamide antibiotic), and metronidazole (a nitroimidazole antibiotic). This combination provides broad-spectrum coverage against gram-positive, gram-negative, and anaerobic bacteria. It is particularly useful for treating complicated infections involving multiple bacterial types, including intra-abdominal infections, complicated skin and soft tissue infections, and polymicrobial infections.

Targets

NeuraminidasePBP (Penicillin-binding protein family)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on ampicillin + clindamycin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ampicillin + clindamycin + metronidazole.

Explore the full profile